Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the closing of its previously announced registered direct offering of an aggregate of (i) 5,050,808 American Depositary Shares (the “Depositary Shares”) (each Depositary Share representing 400 of the Company's ordinary shares, nominal value £0.001 per share) and (ii) 278,975 pre-funded warrants exercisable for Depositary Shares, at a purchase price of $0.94 per Depositary Share (or $0.9399 per pre-funded warrant). The net proceeds from the offering were approximately $4.2 million, after deducting placement agent fees and other offering expenses.

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 19, 2024 Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into definitive agreements with certain institutional investors to sell an aggregate of (i) 5,050,808 American Depositary Shares (the “Depositary Shares”) (each Depositary Share representing 400 of the Company's ordinary shares, nominal value £0.001 per share) and (ii) 278,975 pre-funded warrants exercisable for Depositary Shares, at a purchase price of $0.94 per Depositary Share (or $0.9399 per pre-funded warrant) in a registered direct offering. The gross proceeds from the offering are expected to be approximately $5.0 million, before deducting placement agent fees and other estimated offering expenses.

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Biodexa Pharmaceuticals PLC BDRX announced progress on eRapa, its drug to treat Familial Adenomatous Polyposis (FAP), an inherited disorder characterized by cancer of the large intestine (colon) and rectum.

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Biodexa Pharmaceuticals (NASDAQ: BDRX ) stock is rocketing higher on Thursday after announcing additional positive results from a Phase 2 clinical trial. According to the company, results from its study of eRapa are going well.

Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making good progress with eRapa™, its drug to treat Familial Adenomatous Polyposis (FAP). FAP is a mostly inherited condition that puts people at a much greater risk of developing colorectal cancer.

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two Patients at Optimal Dose, Median Overall Survival Across all Patients was 16.5 Months (vs 10.0 Months in Historical Reference Cohort) (DATELINE) JULY 2 -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces data from a Phase 1 study of MTX110 in Diffuse Midline Glioma (“DMG”) f/k/a Diffuse Intrinsic Pontine Glioma, or DIPG, an orphan pediatric brain cancer were presented over the weekend at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) in Philadelphia, PA. Results of the Phase 1 study Overall, the treatment was well tolerated by patients.

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

June 24, 2024 Biodexa Pharmaceuticals PLC Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) Overall 75% Non-progression Rate at 12 Months Median Decrease in Overall Polyp Burden at 12 Months of 17% Cohort 2 Non-progression Rate at 12 months of 81% and Median Decrease in Poly Burden of 29% Informs Phase 3 Dosage Regimen Data Reported in Oral Presentation at 2024 Bi-Annual InSIGHT Meeting (DATELINE) JUNE 24 -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced that 12 month results of a Phase 2 clinical trial of eRapa™ in Familial Adenomatous Polyposis (“FAP”) (NCT04230499) were reported in an oral presentation at the prestigious 2024 InSIGHT bi-annual meeting in Barcelona by Carol Burke, M.D., a specialist gastroenterologist at the Cleveland Clinic and a leading authority in FAP, a mostly genetic disease of precancerous polyps for which the only current remedy is surgical removal of the colon and/or rectum.

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

13 June 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held earlier today, all resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#company-information.

Results of Annual General Meeting

June 10, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024. Carol Burke, MD, the Principal Investigator, will present the six and 12 month data (NCT04230499) in an oral presentation at the meeting.

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

CARDIFF, UK / ACCESSWIRE / June 3, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) just announced promising phase 2 results for its newly in-licensed drug eRapa for treating familial adenomatous polyposis (FAP), a mainly genetic disease of the lower GI tract for which there is currently no remedy except surgical removal of the colon and/or rectum. In a clinical trial involving 30 adult patients, three groups received the same dose of the drug but with different regimens over a period of 12 months.

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

May 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants (“Series E Warrants”) and Series F warrants (“Series F Warrants,” and together with the Series E Warrants, the “Existing Warrants”) to purchase up to an aggregate of 4,358,322 of the Company's American Depositary Shares (“ADSs) (each ADS represents 400 ordinary shares, nominal value £0.001 of the Company (“Ordinary Shares”)). Stephen Stamp, CEO and CFO, commented, “These funds will more than cover our first year obligation under the eRapa Phase 3 trial in Familial Adenomatous Polyposis and, because the $17 million CPRIT grant includes a one-for-two match, will unlock twice that amount in non-dilutive funding.

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) opened more than 100% up on Tuesday after reporting encouraging Phase 2 data for eRapa.

Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why

May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting Overall 83% non-progression rate at 6 Months Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04) Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) (NCT04230499) are scheduled for presentation at the prestigious 2024 Digestive Disease Week annual meeting in Washington D.C.. Carol Burke, MD, the Principal Investigator, will present the six month data in a podium presentation at the meeting.

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals (NASDAQ: BDRX ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 15.8 million shares of BDRX stock changing hands as of this writing.

Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?

Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by Biodexa, its second portfolio expansion in less than six months, and is supported by a $17 million grant from the State of Texas.

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

April 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024. Carol Burke, MD, the Principal Investigator, will present the six month data (NCT04230499) in an oral presentation at the meeting.

Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

Oncology specialist Biodexa (NASDAQ: BDRX ) soared on Friday as the company disclosed the entering of an exclusive worldwide license to develop and commercialize a key therapeutic. Fundamentally, the announcement sent BDRX stock flying up about 70% in the late afternoon session as the drug addresses a disease for which there are no approved therapeutic options.

Why Is Biodexa (BDRX) Up 70% Today?

April 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum In FAP, eRapa holds the potential of delaying or preventing surgical intervention Multiple opportunities seen in other indications, including bladder and prostate cancers FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24 Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25 Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced it entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) (“Emtora”) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa.       Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa's oncology pipeline and adds numerous valuation catalysts for our stakeholders.

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

19 April 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its audited preliminary results for the year ended 31 December 2023. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs.

Preliminary Results for the Year Ended 31 December 2023

Biodexa Pharmaceuticals (NASDAQ: BDRX ) stock is rising higher on Thursday after the clinical-stage biopharmaceutical company announced positive results from one of its brain cancer treatments. According to a press release from the company, early trials of MTX110 are showing promising results for patients suffering from brain cancer.

Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?

Topline Results For Progression-Free Survival Expected In Q2 2024 CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults; two aggressive brain cancers with universally poor prognoses. The company says early trials of MTX110 in both cancers show promise in extending survival rates beyond those reported in previously published studies.

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin Topline data from Phase 2a program expected by year-end Safety profile established in more than 700 patients CARDIFF, UK / ACCESSWIRE / March 1, 2024 / While type 2 diabetes is frequently discussed in the media, the 1.3 million U.S. adults who struggle with type 1 diabetes are sometimes forgotten about. Type 1 diabetes is a chronic autoimmune condition in which the body's immune system attacks and destroys the insulin-producing cells in the pancreas.

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months vs 10.0 months in Comparable Cohort CARDIFF, United Kingdom, February 23, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, announces an R&D update including positive top-line clinical trial results of a recently completed Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG, and results of a preclinical experiment designed to demonstrate tolimidone's potential for beta cell proliferation in an in vitro model. MTX110 In an investigator initiated study conducted by Columbia University Irving Medical Center, patients newly diagnosed with DMG were administered MTX110 via convection enhanced delivery (“CED”) using a subcutaneous pump connected to a catheter directly implanted into the pons in a 3+3 dose-escalating design (NCT 04264143).

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare/orphan brain cancers, today provided survival updates from its MAGIC-G1 study (NCT05324501) of MTX110 in patients with recurrent glioblastoma (“rGBM”) being conducted at Duke Cancer Institute and Baptist MD Anderson Cancer Center. In October 2023, Biodexa announced completion of recruitment of Cohort A of an ongoing open-label Phase I dose-escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (“CED”) via implanted refillable pump and catheter.

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, today announced that Stephen Stamp, CEO and CFO of Biodexa, has issued a Shareholder Letter highlighting the Company's progress in 2023 and expected milestones in 2024. The full text of the letter follows: Dear Shareholders, I thought now would be a good time to review our Company's progress in 2023 and our plans and expected milestones for 2024, the latter being set out in the following graphic: Last year proved to be a year of transition for our Company.

News for Biodexa Pharmaceuticals Plc Stock (BDRX)